Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own16.20% Shs Outstand65.85M Perf Week9.35%
Market Cap770.44M Forward P/E- EPS next Y-1.60 Insider Trans-0.70% Shs Float52.80M Perf Month5.41%
Income-92.10M PEG- EPS next Q-0.42 Inst Own53.90% Short Float32.41% Perf Quarter11.96%
Sales0.20M P/S3852.22 EPS this Y-15.70% Inst Trans0.49% Short Ratio10.30 Perf Half Y172.09%
Book/sh1.90 P/B6.16 EPS next Y10.60% ROA-105.70% Target Price24.14 Perf Year97.30%
Cash/sh1.66 P/C7.04 EPS next 5Y- ROE-135.30% 52W Range4.10 - 15.35 Perf YTD151.61%
Dividend- P/FCF- EPS past 5Y40.90% ROI- 52W High-23.78% Beta1.21
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low185.37% ATR0.58
Employees63 Current Ratio6.00 Sales Q/Q0.00% Oper. Margin- RSI (14)59.96 Volatility5.34% 5.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-84.20% Profit Margin- Rel Volume0.77 Prev Close11.20
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume1.66M Price11.70
Recom1.40 SMA207.64% SMA503.22% SMA20042.08% Volume1,278,398 Change4.46%
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Mar-07-14Reiterated MLV & Co Buy $9 → $11
Nov-25-13Reiterated Ladenburg Thalmann Buy $8 → $12
Nov-06-13Initiated MLV & Co Buy $9
Jul-14-17 05:08PM  ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube
Jun-28-17 09:02AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube
Jun-26-17 07:30AM  TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire
07:00AM  TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire
Jun-21-17 06:48PM  Cramer's lightning round: This defeated stock is like flypaper CNBC
Jun-16-17 05:45AM  TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-15-17 04:21PM  New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool
03:27PM  ETFs with exposure to TG Therapeutics, Inc. : June 15, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire
04:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-14-17 12:00PM  TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma GlobeNewswire +5.16%
Jun-13-17 09:29AM  Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool
08:51AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 13, 2017 Capital Cube
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress GlobeNewswire
Jun-08-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire +5.69%
Jun-06-17 08:49AM  Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock? Zacks
07:30AM  TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
Jun-05-17 02:50PM  ETFs with exposure to TG Therapeutics, Inc. : June 5, 2017 Capital Cube -6.14%
10:56AM  U.S. stocks look for direction in shadow of U.K. terror attacks MarketWatch
09:43AM  Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal
09:37AM  UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results MarketWatch
09:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire
Jun-03-17 06:00PM  TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
Jun-02-17 05:37PM  Why TG Therapeutics Inc Jumped Higher Today Motley Fool +17.37%
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
May-26-17 12:46PM  5 Stocks Setting Up for Big Breakouts TheStreet.com
May-23-17 12:46PM  TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL TheStreet.com
07:30AM  TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial GlobeNewswire
May-22-17 08:17AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22, 2017 Capital Cube
May-19-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire
May-18-17 06:05AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire
May-17-17 05:05PM  TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
May-15-17 04:44PM  ETFs with exposure to TG Therapeutics, Inc. : May 15, 2017 Capital Cube
May-12-17 10:55AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube +6.33%
May-11-17 07:41PM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : May 11, 2017 Capital Cube
May-10-17 08:16AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 10, 2017 Capital Cube
May-05-17 08:22AM  3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool
07:42AM  TG Therapeutics reports 1Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 04:30PM  TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update GlobeNewswire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool
Apr-28-17 08:30AM  TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting GlobeNewswire -7.53%
Apr-26-17 03:38PM  ETFs with exposure to TG Therapeutics, Inc. : April 26, 2017 Capital Cube
03:23PM  Harry Boxers two infrastructure stocks to watch MarketWatch
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics Accesswire
Apr-25-17 06:59PM  Why TG Therapeutics Inc. Jumped Higher Today Motley Fool +15.38%
11:40AM  Potential FDA Controversy Brewing For TG Therapeutics? Benzinga
Apr-24-17 07:30AM  TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting GlobeNewswire
Apr-21-17 10:57AM  Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics Benzinga
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com
02:00PM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
Apr-18-17 07:30AM  FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire
Apr-07-17 08:30AM  Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Zacks
Apr-04-17 01:22PM  TG Therapeutics stock rises 2% on preclinical data for cancer drug MarketWatch
01:22PM  TG Therapeutics stock rises 2% on preclinical data for cancer drug
01:00PM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting GlobeNewswire
01:00PM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
Apr-03-17 04:23PM  3 Top Biotech Stocks to Buy in April Motley Fool -5.15%
04:23PM  3 Top Biotech Stocks to Buy in April at Motley Fool
Mar-30-17 10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
10:33AM  5 Top Performing Stocks of the Best ETF of Q1
Mar-27-17 04:07PM  ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 Capital Cube
04:07PM  ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017
Mar-22-17 01:04PM  TG THERAPEUTICS, INC. Financials -5.53%
08:32AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Capital Cube
08:32AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017
Mar-20-17 07:30AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-19-17 01:51PM  Don't Let Offerings Blindside Your Thesis
Mar-17-17 07:30AM  TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-16-17 09:30AM  TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Accesswire
06:11AM  TG THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-13-17 07:30AM  TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference GlobeNewswire +7.02%
Mar-10-17 07:54AM  TG Therapeutics reports 4Q loss
07:37AM  Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
07:34AM  TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire
07:07AM  Q4 2016 TG Therapeutics Inc Earnings Release - After Market Close
Mar-09-17 05:06PM  TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme +16.26%
04:30PM  TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire
09:19AM  TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock GlobeNewswire
Mar-08-17 04:01PM  TG Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -6.88%
Mar-07-17 07:20PM  Cramer's lightning round: Best-in-show pipeline stocks at CNBC +6.86%
01:55PM  Harry Boxers six biotechnology stocks to watch at MarketWatch
11:48AM  Heres Whats Next For TG Therapeutics Inc (TGTX) at Insider Monkey
10:25AM  DEADLINE TODAY FOR TGTX INVESTORS: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:03AM  DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 - TGTX PR Newswire
Mar-06-17 05:35PM  Tyson and Deutsche Bank slide; Southwestern Energy jumps +90.65%
04:35PM  Why Range Resources, Central European Media Enterprises, and TG Therapeutics Jumped Today at Motley Fool
03:53PM  TG Therapeutics Surges 85% on Results From Study
01:45PM  Mondays Top Health Care Stocks Screaming Higher
01:36PM  How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More
01:15PM  Why TG Therapeutics Stock Exploded Higher Today at Motley Fool
11:27AM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
10:35AM  TG Therapeutics' leukemia drug clears key study, shares pop
07:39AM  TG Therapeutics' stock shoots up toward 5-month high after positive test results at MarketWatch
07:22AM  TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:14AM  TG Therapeutics' leukemia drug clears hurdle in key study
07:00AM  TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) GlobeNewswire
Mar-03-17 08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX Accesswire
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Power Sean ACFO, Secretary and TreasurerJun 19Sale11.0430,000331,200447,464Jun 19 06:05 PM
Power Sean ACFO, Secretary and TreasurerJun 16Sale11.1429,976333,933477,464Jun 19 06:05 PM
KENNEDY WILLIAM JAMESDirectorApr 11Sale10.278,54887,78870,401Apr 12 05:44 PM
Charney Laurence NDirectorApr 04Sale11.177,00078,19088,949Apr 04 05:57 PM
Power Sean ACFO, Secretary and TreasurerJan 04Sale4.558,81640,113507,440Jan 04 05:28 PM